Skip to main content

Table 3 Subgroup survival analysis for patients with early- and late-stage breast cancer (%)

From: The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study

Characteristic

Early-stage

Late-stage

Total (cases)

5-year OS rate (%)

P valueb

5-year CSS rate (%)

P valueb

Total (cases)

5-year OS rate (%)

P valueb

5-year CSS rate (%)

P valueb

Histological grade

< 0.01

 

< 0.01

  

< 0.01

 

< 0.01

 Well differentiated

283

96.8

 

97.5

 

25

92.0

 

92.0

 

 Moderately differentiated

1971

94.3

 

95.0

 

359

74.7

 

76.0

 

 Poorly differentiated

685

90.3

 

91.3

 

155

60.1

 

61.4

 

 Unknowna

575

92.7

 

94.0

 

134

63.2

 

63.2

 

Histological type

0.66

 

0.41

  

0.89

 

0.73

 Ductal

3089

93.4

 

94.1

 

597

70.1

 

71.2

 

 Lobular

103

92.1

 

95.0

 

26

63.9

 

63.9

 

 Others

322

94.1

 

95.6

 

50

67.9

 

67.9

 

Molecular subtype

< 0.01

 

< 0.01

  

< 0.01

 

< 0.01

 Luminal A

1897

95.2

 

95.8

 

299

77.1

 

77.8

 

 Luminal B

390

94.0

 

94.2

 

90

69.1

 

71.3

 

 HER2

256

90.9

 

92.4

 

78

58.3

 

61.7

 

 Triple-negative

371

88.6

 

89.4

 

91

60.4

 

60.4

 

 Unknowna

600

91.7

 

93.3

 

115

65.8

 

65.8

 
  1. Of the total 4640 patients, 453 with unknown stage at diagnosis were not included in the analysis
  2. OS overall survival, CSS cancer-specific survival
  3. aUnknown data were not included in the statistical tests
  4. b P values were calculated using log-rank test
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us